Metformin for Anti-Aging & Longevity: Evidence, Dosage & Alternatives (2026)

What Is Metformin and Why Do People Take It for Anti-Aging?

Metformin (brand name Glucophage) is a biguanide drug prescribed to over 150 million people worldwide for type 2 diabetes. It has been in clinical use since the 1950s in Europe and since 1995 in the United States. That makes it one of the most prescribed and best-studied drugs in history.

Its core mechanism involves activating AMP-activated protein kinase (AMPK), often described as the cell's energy sensor. When AMPK is active, cells shift from growth mode to maintenance and repair mode: increasing autophagy (cellular cleanup), improving mitochondrial function, reducing hepatic glucose production, and suppressing the mTOR pathway that drives cell growth. These are the same metabolic shifts that occur during caloric restriction and fasting, which is why metformin is sometimes called a "caloric restriction mimetic."

The anti-aging interest began with observational data. A 2014 study from the UK Clinical Practice Research Datalink examined over 180,000 patients and found that diabetic patients taking metformin had approximately 15% lower all-cause mortality than matched non-diabetic controls. That finding was striking: people with a metabolic disease, taking a single drug, appeared to outlive people without the disease. Animal data supported the hypothesis. Metformin extended lifespan in C. elegans (nematode worms) and in some mouse strains, though the mouse results have been inconsistent across genetic backgrounds and doses.

These converging signals prompted Nir Barzilai, M.D., at the Albert Einstein College of Medicine to propose the TAME trial, a landmark effort to test metformin specifically as an anti-aging intervention in humans.

Where Does the TAME Trial Stand in 2026?

TAME (Targeting Aging with Metformin) is the most consequential aging trial currently running, not because metformin is necessarily the best anti-aging compound, but because it created the first regulatory framework for treating aging as a clinical target.

The trial design: randomized, double-blind, placebo-controlled, testing metformin 1,500 mg/day (extended-release) versus placebo in non-diabetic adults aged 65-79. The primary endpoint is a composite of time to first occurrence of cardiovascular disease, cancer, cognitive impairment, or death. Approximately 3,000 participants across 14 US centers. The FDA agreed to accept this composite aging endpoint, marking the first time aging itself was treated as a legitimate target for drug evaluation.

As of mid-2026, the trial is active and still enrolling. No efficacy data has been published. Given the 4-6 year follow-up period, primary results are unlikely before 2027-2028 at the earliest. Interim biomarker papers will likely appear before the primary outcome data.

The trial has faced significant obstacles. Congressional budget uncertainty and proposed cuts to NIA (National Institute on Aging) funding created financial pressure. ARPA-H (the Advanced Research Projects Agency for Health) became involved in funding, and Eli Lilly has launched a parallel aging trial using TAME's FDA framework, validating the regulatory pathway even if TAME's own results take years to arrive.

What makes TAME irreplaceable is the precedent, not the molecule. If it shows that metformin delays multiple age-related diseases simultaneously, the FDA would have reason to recognize aging as a modifiable condition. That would open the door for rapamycin, senolytics, NAD+ precursors like NMN, and eventually reprogramming therapies to pursue aging-specific indications.

What Evidence Supports Metformin for Longevity?

The case for metformin rests on three pillars: mechanism, animal data, and human observational evidence. Each has real substance, and each has real limitations.

Mechanism

Metformin activates AMPK and inhibits mTOR, which are two of the most validated aging pathways identified in the 12 hallmarks of aging framework. AMPK activation promotes autophagy, improves mitochondrial quality control, and reduces chronic inflammation. mTOR inhibition shifts cells from proliferative programs toward repair and maintenance. These are the same pathways that caloric restriction, exercise, and other longevity interventions target.

Metformin also reduces hepatic glucose output, lowers circulating insulin levels, and improves insulin sensitivity. Since hyperinsulinemia and insulin resistance are associated with accelerated biological aging, this metabolic normalization may itself be geroprotective.

Animal data

Metformin extended lifespan in C. elegans (roundworms) through effects on folate and methionine metabolism in gut bacteria. In mice, the results are mixed. The Interventions Testing Program (ITP), which tests compounds across three independent labs using genetically heterogeneous mice, found that metformin extended lifespan in males started on treatment at 9 months but not in other cohorts. Other labs have reported lifespan extension in specific mouse strains (C57BL/6), but the effect is smaller and less consistent than what rapamycin produces across studies.

This inconsistency matters. Rapamycin extends lifespan in essentially every organism tested, across strains, labs, and dosing protocols. Metformin does so in some contexts and fails in others. The compound specificity of the effect raises questions about how broadly it translates.

Human observational data

The 2014 UK study (Bannister et al.) finding lower mortality in metformin-treated diabetics compared to non-diabetic controls remains the most cited evidence. But observational studies carry inherent confounding. Metformin users are actively managed by physicians, more likely to receive other preventive care, and selected for treatment precisely because they have treatable metabolic disease. The "healthy user" bias and "time-related bias" described by Keys et al. (2025) in Ageing Research Reviews make it difficult to isolate metformin's independent effect from confounding variables.

The MILES (Metformin In Longevity Study) trial, an earlier human study, showed that metformin induced changes in gene expression that partially overlapped with profiles seen in caloric restriction. This was a transcriptomic finding, not a clinical outcome, and it is not clear whether transcriptional changes translate to functional aging benefits.

What Evidence Weakens the Case for Metformin? (2025-2026 Updates)

Recent clinical trials have produced results that challenge the metformin-as-longevity-drug narrative. Three studies stand out.

DPP 21-year follow-up (JAMA, June 2026)

The Diabetes Prevention Program Outcomes Study (DPPOS) published a 21-year follow-up in JAMA in 2026 (Salive et al., PMID 42295772). This is the longest randomized data comparing metformin versus lifestyle intervention versus placebo in adults with prediabetes. The headline finding: intensive lifestyle intervention (diet + exercise) significantly reduced the risk of multimorbidity, while metformin did not. For people interested in longevity, this is a sobering result. The longest controlled human dataset available says exercise and diet beat metformin for preventing the accumulation of age-related diseases.

MET-PREVENT trial (Lancet Healthy Longevity, 2025)

The MET-PREVENT trial (Witham et al., 2025, PMID 40147475) tested metformin in older adults with sarcopenia or pre-sarcopenia for four months. The result: metformin did not improve grip strength, walking speed, physical performance, muscle mass, quality of life, or activities of daily living. The trial also reported that metformin was poorly tolerated by the study population, a common problem in frail elderly participants where GI side effects disproportionately affect adherence and quality of life.

MASTERS trial: metformin blunts exercise gains

The MASTERS trial (Walton et al., 2019, PMID 31557380) tested metformin alongside a 14-week progressive resistance training program in healthy adults over 65. The placebo group gained significantly more lean body mass (p = .003) and thigh muscle mass (p < .001) than the metformin group. CT scans confirmed that increases in thigh muscle area (p = .005) and density (p = .020) were greater in placebo versus metformin.

The mechanism appears to involve metformin's AMPK activation directly opposing the mTOR signaling required for muscle protein synthesis. In other words, the same pathway that makes metformin theoretically interesting for anti-aging (AMPK up, mTOR down) also makes it counterproductive for people who rely on resistance training to maintain muscle mass, which is itself one of the strongest predictors of healthy aging.

A 2025 review by Keys et al. in Ageing Research Reviews (PMID 40582648), titled "Emerging uncertainty on the anti-aging potential of metformin," synthesized these and other findings and concluded that the evidence base for metformin as a geroprotector is weaker than commonly presented. The review noted that most positive human data comes from observational studies susceptible to time-related biases, while controlled trials have largely failed to demonstrate the functional benefits that longevity-seekers hope for.

What Is the Anti-Aging Dosage for Metformin?

There is no validated anti-aging dose for metformin. The TAME trial uses 1,500 mg/day (extended-release, taken as 750 mg twice daily). Longevity physicians who prescribe off-label typically start at 500 mg/day and titrate upward based on tolerance, often landing at 1,000-1,500 mg/day.

The diabetes dose range is 500-2,550 mg/day. Most anti-aging protocols stay at the lower end of this range, partly to reduce side effects and partly because the theoretical longevity mechanism (AMPK activation) may not require the higher doses used for aggressive glycemic control.

Extended-release (ER) formulations are preferred for off-label use because they substantially reduce GI side effects compared to immediate-release. The cost is roughly $4-10/month for generic metformin ER, making it one of the cheapest pharmaceutical interventions available.

Timing: most users take metformin with dinner or before bed. The rationale is that metformin primarily reduces hepatic glucose output, which peaks overnight. Some longevity physicians recommend separating metformin from exercise by at least 4-6 hours to reduce the training-blunting effect, though this strategy has not been tested in a controlled trial.

What Are the Side Effects and Risks?

Metformin's side effect profile is well-documented from decades of diabetes use:

Gastrointestinal distress is the most common complaint. Nausea, diarrhea, bloating, and abdominal discomfort affect up to 25% of users, especially during the first 2-4 weeks. Extended-release formulations reduce but do not eliminate this. The MET-PREVENT trial noted that tolerability was particularly poor in frail older adults.

Vitamin B12 depletion occurs with long-term use and is often undermonitored. A 2019 meta-analysis found that metformin use was associated with a 17% increased risk of B12 deficiency. Before reaching for a prescription, it's worth reviewing the best anti-aging supplements with fewer trade-offs. Since B12 deficiency can cause peripheral neuropathy and cognitive symptoms that mimic aging, this is especially relevant in a longevity context. Annual B12 monitoring and supplementation are standard recommendations for long-term users.

Exercise blunting is real, as described above. For people who exercise consistently, especially with resistance training, this is potentially the most important downside. If exercise is the single most validated longevity intervention in humans, and metformin reduces the effectiveness of exercise, the net longevity effect could be negative.

Lactic acidosis is rare but serious, occurring primarily in patients with impaired kidney function. Healthy adults using metformin off-label at standard doses face very low risk, but kidney function should be monitored periodically.

Metformin is a prescription drug. It cannot be obtained legally without a physician's prescription in the US. Off-label use for longevity is legal (physicians can prescribe any FDA-approved drug for any purpose) but insurance may not cover it for this indication.

How Does Metformin Compare to NMN?

Metformin and NMN both appear in longevity conversations, but they target different aging mechanisms through different approaches.

Pathway: Metformin activates AMPK and inhibits mTOR (nutrient-sensing pathways). NMN restores NAD+, supporting sirtuin activity, DNA repair, and mitochondrial function. These are complementary, not competing, mechanisms within the 12 hallmarks of aging.

Human evidence for the primary claim: Metformin's AMPK activation in humans is established, but no controlled trial has shown it slows aging in healthy adults. NMN's NAD+-doubling effect (detailed in our NAD+ supplement guide) is confirmed in a 2026 Nature Metabolism head-to-head trial (Christen et al., 65 adults, 14 days), but whether that NAD+ increase translates to measurable healthspan extension is still being studied.

Access: Metformin requires a prescription. NMN is available over the counter as a dietary supplement in the US.

Exercise interaction: Metformin blunts muscle hypertrophy from resistance training (MASTERS trial). NMN has not shown this effect; the Morifuji 2024 trial actually showed improved physical function (walking speed) in older adults taking 250 mg/day.

Side effects: Metformin causes GI distress in up to 25% of users, depletes B12, and interferes with exercise adaptation. NMN is well-tolerated at doses up to 1,250 mg/day in published safety trials, with no serious adverse events reported.

Cost: Metformin is cheaper ($4-10/month for generic). NMN ranges from $30-60/month depending on dose and brand. See our NMN supplement guide for how to evaluate quality and cost.

Stack potential: Some longevity physicians recommend both together, arguing that AMPK activation (metformin) plus NAD+ restoration (NMN) covers two major aging pathways simultaneously. This combination has not been tested in a clinical trial, and the theoretical logic does not account for the exercise-blunting interaction. David Sinclair has publicly disclosed taking both NMN and metformin as part of his personal protocol, though he has noted this is a personal choice, not a clinical recommendation. For more on Sinclair's protocol, see our NMN and resveratrol analysis.

Is Berberine an OTC Alternative to Metformin?

For people who want AMPK activation without a prescription, berberine is the closest over-the-counter parallel. Both compounds activate AMPK, reduce hepatic glucose output, and improve insulin sensitivity.

A 2008 head-to-head trial (Yin et al., Metabolism) compared berberine 500 mg three times daily to metformin 500 mg three times daily in patients with type 2 diabetes. Berberine reduced HbA1c and fasting glucose comparably to metformin. Subsequent meta-analyses have confirmed comparable glucose-lowering effects.

The key differences: berberine has lower bioavailability than metformin (typically 5-10% absorption), which means higher doses are needed to achieve systemic levels. Berberine also lacks the depth of long-term safety data that metformin has accumulated over 60+ years of prescription use. And berberine does not have a TAME-equivalent trial testing it specifically for aging.

For dosing, see our berberine dosage guide. The standard protocol from positive clinical trials is 500 mg two to three times daily with meals.

Should You Take Metformin for Anti-Aging?

The honest answer depends on who you are.

If you have type 2 diabetes or prediabetes: Metformin is a well-supported first-line treatment with decades of safety and efficacy data. Any longevity benefit would be a bonus on top of its established metabolic effects.

If you are metabolically healthy and exercise regularly: The case is weak. No controlled trial has shown metformin benefits healthy adults. The MASTERS trial showed it actively interferes with resistance training adaptations. The DPP 21-year follow-up showed lifestyle intervention (which includes exercise) outperformed metformin for preventing multimorbidity. Taking a drug that blunts the effect of the single most validated longevity intervention (exercise) is a difficult trade-off to justify.

If you are metabolically healthy and sedentary: The case is uncertain. Metformin's metabolic benefits may be more relevant in people who are not getting those benefits from exercise. But no trial has tested this specific population for aging outcomes, and the MET-PREVENT results in sedentary older adults were negative.

The responsible position in 2026 is to wait for TAME. If you want to act now rather than wait, the evidence is stronger for exercise, sleep optimization, and Mediterranean-pattern eating than for any pharmaceutical intervention. For supplemental support, NMN for NAD+ restoration and berberine for AMPK activation offer OTC alternatives that target complementary aging pathways without the exercise-blunting trade-off, though their evidence base is also still developing.

Metformin Anti-Aging Before and After: What Users Report

Online communities dedicated to longevity, particularly Reddit's r/longevity and r/Metformin, contain thousands of self-reports from people taking metformin off-label for anti-aging. The pattern that emerges is consistent but not dramatic.

The most commonly reported positive effects are improved fasting glucose (typically dropping 5-15 mg/dL from already-normal levels), slight reductions in fasting insulin, and a subjective sense of metabolic "stability" that users describe as fewer energy crashes after meals. Some users report modest fat loss, particularly visceral fat, though this effect overlaps heavily with the GI side effects that reduce appetite in the first few weeks.

The most commonly reported negative effects are exactly what the clinical literature predicts: GI disturbance (nausea, diarrhea, bloating) that subsides over 2-4 weeks for most users but persists indefinitely for some; reduced exercise performance, particularly in strength training; and fatigue that some users attribute to B12 depletion or mitochondrial effects.

What users rarely report is anything that looks like "anti-aging" in the way supplement marketing implies. There are no credible user reports of reversed gray hair, visibly younger skin, dramatic energy increases, or cognitive transformation. The subjective experience of metformin for most healthy users is mild metabolic improvement with noticeable GI trade-offs.

Before-and-after bloodwork comparisons posted by longevity community members typically show reduced fasting glucose, reduced fasting insulin, and sometimes improved lipid ratios. These are metabolic markers, not aging markers. Biological age testing (epigenetic clocks) before and after metformin use has been reported by a small number of users with mixed results; no controlled study has assessed whether metformin reduces epigenetic age in healthy adults.

For comparison, users who track NMN supplementation with before-and-after bloodwork most commonly report elevated NAD+ levels and, in some cases, reduced biological age on epigenetic clock tests. The NMN before and after evidence from clinical trials shows measurable NAD+ doubling within 14 days and improved walking speed at 12 weeks in older adults.

Who Prescribes Metformin for Longevity?

Metformin for anti-aging is typically prescribed by longevity medicine physicians, functional medicine practitioners, and anti-aging clinics. It is not a standard recommendation from primary care physicians, endocrinologists, or geriatricians outside the diabetes and prediabetes indications.

The American College of Physicians and the Endocrine Society have not endorsed metformin for longevity. The American Diabetes Association's 2026 Standards of Care recommend metformin for diabetes prevention in high-risk adults (ages 25-59, BMI over 35, elevated glucose or A1C, or history of gestational diabetes), but this is a diabetes prevention recommendation, not an anti-aging one.

Longevity physicians who prescribe metformin off-label typically frame it as one component of a multi-pathway protocol. Common co-prescriptions include rapamycin (low-dose, weekly), NAD+ precursors (NMN or NR), and lifestyle optimization (structured exercise, sleep protocols, Mediterranean-pattern diet).

The cost of a longevity physician consultation ranges from $300-1,000 for an initial visit, with quarterly follow-ups at $150-400. Metformin itself costs $4-10/month at retail pharmacies with a prescription. The physician cost, not the drug cost, is the main financial barrier for off-label use.

Some online telehealth platforms now offer longevity-focused consultations that include metformin prescriptions as part of subscription packages ($99-299/month). These services vary widely in physician quality and protocol rigor. The key question to ask any prescriber: "What evidence supports metformin in someone with my metabolic profile?" If the answer references only observational data and animal studies, that is the current state of the evidence, and you should be aware that it is incomplete.

How Does Metformin Interact with Other Longevity Supplements?

People building longevity protocols often combine metformin with supplements. Here is what is known about the major interactions.

Metformin + NMN: No pharmacological interaction has been identified. Metformin activates AMPK; NMN restores NAD+ through the NAMPT-NMNAT pathway. These are mechanistically complementary. David Sinclair has disclosed taking both. However, combining two interventions that individually lack definitive human aging data does not create definitive evidence through combination. Timing: NMN is typically taken in the morning; metformin with dinner or before bed. This temporal separation avoids any theoretical competition for absorption.

Metformin + Berberine: Both activate AMPK and reduce hepatic glucose output. Taking both together could theoretically produce excessive glucose-lowering, increasing the risk of hypoglycemia, especially in non-diabetic users. Most longevity physicians recommend one or the other, not both. If you choose berberine specifically because you want to avoid a prescription, adding metformin defeats the purpose. For berberine dosing, the standard clinical protocol is 500 mg two to three times daily with meals.

Metformin + Rapamycin: Both are used in longevity protocols. There is no known drug-drug interaction at the doses used off-label. Some longevity physicians prescribe both, arguing that AMPK activation (metformin) and mTOR inhibition (rapamycin) are synergistic. The counterargument is that both suppress mTOR, potentially over-suppressing an essential growth and repair pathway. No trial has tested this combination for aging.

Metformin + Exercise: This is the most evidence-based interaction, and it is negative. The MASTERS trial clearly showed metformin blunts resistance training adaptations. For people who prioritize exercise as their primary longevity strategy (and the evidence says they should), this interaction alone may disqualify metformin from their protocol. Some users attempt to time metformin away from workouts (taking it only on rest days or only at night after morning exercise), but this approach has not been validated.

Metformin + Vitamin B12: Long-term metformin use depletes B12 through impaired absorption in the ileum. Annual B12 monitoring is recommended for all long-term users. Supplementation with methylcobalamin (1,000 mcg/day) is standard practice among longevity physicians prescribing metformin.

What Is the Bottom Line on Metformin for Anti-Aging?

Metformin is a fascinating compound with a compelling mechanistic story. It activates the right pathways (AMPK, autophagy) at an unbeatable price ($4/month) with 60 years of safety data behind it. If TAME reports positive results, it will change the trajectory of aging medicine.

But the controlled human data available in 2026 paints a more complicated picture than the longevity community's enthusiasm suggests. The DPP 21-year follow-up found lifestyle beat metformin for multimorbidity prevention. MET-PREVENT found metformin did not improve physical function in older adults. The MASTERS trial found metformin blunted the single most effective anti-aging intervention available: exercise.

The honest recommendation: if you are diabetic or prediabetic, metformin is well-supported for metabolic health. If you are metabolically healthy, particularly if you exercise, the evidence does not currently justify off-label use. Wait for TAME. In the meantime, the interventions with the strongest current evidence for healthy aging are exercise, sleep, diet, and select supplements that do not interfere with training adaptations.

For OTC supplementation targeting aging pathways, NMN (NAD+ restoration, 250-500 mg/day) and berberine (AMPK activation, 1,000-1,500 mg/day) cover two of the same mechanisms metformin targets, without requiring a prescription and without the demonstrated exercise-blunting effect. Their evidence base is also still developing, but neither has shown the negative interactions that complicate metformin's longevity case.

Frequently Asked Questions

Does metformin actually slow aging?

No controlled trial has demonstrated that metformin slows aging in healthy humans. The TAME trial is designed to answer this question, but results are not expected before 2027-2028. The evidence that exists comes primarily from observational studies in diabetic populations, animal models with inconsistent results, and mechanistic data showing AMPK activation. A 2025 review in Ageing Research Reviews concluded that the anti-aging evidence for metformin is weaker than commonly presented, particularly when observational study biases are accounted for.

Is metformin better than exercise for longevity?

No. The 21-year DPP follow-up published in JAMA in 2026 directly compared lifestyle intervention (diet and exercise) versus metformin in the longest randomized dataset available. Lifestyle intervention reduced multimorbidity risk; metformin did not. On top of that, the MASTERS trial showed metformin actively blunts muscle hypertrophy from resistance training. Exercise remains the single most validated longevity intervention in humans, and metformin may interfere with its benefits.

Can I take metformin and NMN together?

There is no known pharmacological interaction between metformin and NMN. They target different aging pathways: metformin activates AMPK, while NMN restores NAD+ through a separate biosynthetic route. Some longevity practitioners recommend both as part of a multi-pathway protocol. David Sinclair has publicly disclosed taking both. However, this combination has not been tested in a controlled trial, and combining two interventions with individually incomplete evidence does not create stronger evidence. For NMN dosing and timing, see our NMN timing guide.

What is the anti-aging dose of metformin?

There is no validated anti-aging dose. The TAME trial uses 1,500 mg/day (extended-release). Off-label longevity use typically ranges from 500-1,500 mg/day, starting low and titrating based on GI tolerance. Most longevity physicians prefer extended-release formulations to reduce side effects. The diabetes dose range (500-2,550 mg/day) is higher than what most anti-aging users take.

Is berberine the same as metformin?

No, but they activate the same primary pathway (AMPK) and produce comparable glucose-lowering effects in head-to-head diabetic trials. Berberine is available over the counter and does not require a prescription. The key differences: berberine has lower bioavailability (5-10% absorption), less long-term safety data, and no aging-specific clinical trial. Metformin has 60+ years of safety data but requires a prescription. Most longevity practitioners recommend one or the other, not both, due to the risk of excessive glucose lowering when combined.

Does metformin cause muscle loss?

The MASTERS trial (2019) showed that metformin reduced lean body mass gains and thigh muscle mass gains from resistance training compared to placebo. This is not "muscle loss" in the sense of active wasting, but rather a blunting of the muscle-building response to exercise. The mechanism involves metformin's AMPK activation suppressing the mTOR signaling required for muscle protein synthesis. For older adults, maintaining and building muscle mass is one of the strongest predictors of healthspan and independence, making this trade-off particularly significant.

Should I stop exercising if I take metformin?

Absolutely not. Exercise remains beneficial even with metformin; the MASTERS trial showed that metformin blunted the muscle response, but it did not eliminate the benefits of training entirely. Placebo subjects gained more, but metformin subjects still gained some. The practical question is whether metformin adds enough longevity benefit on top of exercise to justify reducing exercise effectiveness. Based on current evidence, for metabolically healthy people who exercise consistently, the answer is likely no.

How long does it take for metformin to work for anti-aging?

This question assumes that metformin "works" for anti-aging, which has not been demonstrated. Metabolic effects (reduced fasting glucose, reduced insulin) typically appear within 1-2 weeks. GI side effects usually peak in the first 2-4 weeks and improve with continued use. Any potential geroprotective effects, if they exist, would likely require years to manifest as measurable health outcomes, which is why TAME has a 4-6 year follow-up period.

Is metformin safe for non-diabetics?

Metformin has been used safely in non-diabetic populations (particularly for prediabetes and PCOS) for decades. The side effect profile in healthy adults is similar to diabetic populations: GI distress in up to 25%, B12 depletion with long-term use, and rare lactic acidosis risk primarily in those with impaired kidney function. The MET-PREVENT trial noted that metformin was poorly tolerated in frail elderly adults. For healthy, younger adults, the safety profile is generally favorable at standard doses with appropriate monitoring.

Sources

1. Salive ME, et al. "Lifestyle and metformin interventions and risk of multimorbidity in adults with prediabetes: 21-year DPP/DPPOS follow-up." JAMA. 2026. PubMed
2. Walton RG, et al. "Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: the MASTERS trial." Aging Cell. 2019;18(6):e13039. PubMed · DOI
3. Keys MT, et al. "Emerging uncertainty on the anti-aging potential of metformin." Ageing Research Reviews. 2025. PubMed
4. Witham MD, et al. "MET-PREVENT randomized trial: metformin for sarcopenia prevention in older adults." Lancet Healthy Longevity. 2025. PubMed
5. Bannister CA, et al. "Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls." Diabetes, Obesity and Metabolism. 2014;16(11):1165-1173. PubMed
6. Christen S, Cuenoud B, et al. "The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans." Nature Metabolism. 2026;8(1):62-73. PubMed
7. Barzilai N, et al. "Metformin as a tool to target aging." Cell Metabolism. 2016;23(6):1060-1065. PubMed
8. Cheng FF, Liu YL, et al. "Metformin's mechanisms in attenuating hallmarks of aging and age-related disease." Aging and Disease. 2022;13(4):970-986. PubMed
9. Kulkarni AS, et al. "Metformin alters skeletal muscle transcriptome adaptations to resistance training in older adults." Aging. 2020;12(20):19852-19866. PubMed
10. Yin J, et al. "Efficacy of berberine in patients with type 2 diabetes." Metabolism. 2008;57(5):712-717. PubMed
11. American Federation for Aging Research. "Targeting Aging with Metformin (TAME)." AFAR
12. Morifuji M, et al. "NMN 250 mg/day 12-week RCT: walking speed, NAD+, and sleep quality in older adults." 2024. PubMed search